Related Experiment Video
Updated: Mar 17, 2026
09:42
Generation of Murine Monoclonal Antibodies by Hybridoma Technology
Published on: January 2, 2017
44.0K
Licensed monoclonal antibodies and associated challenges
Human Antibodies
|July 30, 2016
Summary
Monoclonal antibodies (mAbs) are effective targeted therapies but can cause adverse events. Continuous monitoring and communication are vital for managing risks associated with these FDA-approved treatments.
Area of Science:
- Immunology
- Pharmacology
- Oncology
Background:
- Monoclonal antibodies (mAbs) represent a significant advancement in targeted therapeutics, demonstrating efficacy across autoimmune diseases, inflammation, infections, and cancers.
- Numerous mAbs have received US Food and Drug Administration (FDA) approval, with many more in development, highlighting their critical role in treating severe conditions.
Purpose of the Study:
- To review the challenges and adverse events associated with FDA-approved monoclonal antibodies (mAbs) from 2007 to 2014.
- To emphasize the importance of monitoring the benefit-to-risk ratio for patients receiving mAb therapy.
Main Methods:
- Literature review focusing on FDA-approved monoclonal antibodies (mAbs).
- Analysis of adverse events reported for mAbs approved between 2007 and 2014.
Main Results:
- While FDA-approved mAbs are pivotal in disease treatment, they are not without risks.
- Commonly associated adverse events include infections, malignancies, and anaphylactoid/anaphylactic reactions.
- The safety profile necessitates careful patient monitoring.
Conclusions:
- The benefit-to-risk assessment of mAbs requires ongoing vigilance.
- Effective management of antibody-based adverse events necessitates collaboration among patients, physicians, biopharmaceutical companies, and researchers.
- Open communication channels are crucial for addressing challenges and ensuring patient safety with mAb therapies.
